Development of multi-epitope vaccines targeting wild-type sequence p53 peptides

Expert Rev Vaccines. 2008 Sep;7(7):1031-40. doi: 10.1586/14760584.7.7.1031.

Abstract

Loss of p53 tumor-suppressor function is the most common abnormality in human cancer, which can result in enhanced presentation to immune cells of wild-type (wt)-sequence peptides from tumor p53 molecules, thus providing the rationale for wt p53 peptide-based cancer vaccines. We review evidence from preclinical murine tumor models and preclinical studies that led to the clinical introduction of wt p53 peptide-based vaccines for cancer immunotherapy. Overall, this review illustrates the complex process of wt p53 epitope selection and the issues and concerns involved in the application of p53-based vaccines for patients with cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Cancer Vaccines / genetics
  • Cancer Vaccines / immunology*
  • Epitopes / genetics
  • Epitopes / immunology*
  • Humans
  • Mice
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Tumor Suppressor Protein p53 / immunology*
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology*

Substances

  • Cancer Vaccines
  • Epitopes
  • Tumor Suppressor Protein p53
  • Vaccines, Synthetic